Clinical Trials · NCT07121153

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

CompletedPhase 1Amycretin (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
36
Start date
Aug 2025
Locations
1 site, China
Primary endpoint
Number of treatment emergent adverse events (TEAEs)
View Amycretin compound reference